Showing 2661-2670 of 5646 results for "".
- Regeneron: Eylea Reduced Risk of Developing Vision-Threatening Events by 75% After 2 Years in Patients With DRhttps://modernod.com/news/regeneron-eylea-reduced-risk-of-developing-vision-threatening-events-by-75-after-two-years-in-patients-with-dr/2477283/Regeneron Pharmaceuticals announced positive 2-year results from the phase 3 PANORAMA trial evaluating Eylea (aflibercept) injection 2 mg (0.05 mL) in patients with moderately severe to severe nonproliferative diabetic retinopathy (NPDR). The data were presented for the first time at the Angiogen
- Aerie Pharmaceuticals Announces Appointment of Michelle Senchyna, PhD, as Vice President, Clinical Development and Medical Affairshttps://modernod.com/news/aerie-pharmaceuticals-announces-appointment-of-michelle-senchyna-phd-as-vice-president-clinical-development-and-medical-affairs/2477271/Aerie Pharmaceuticals announced the appointment of Michelle Senchyna, PhD, as Vice President, Clinical Development and Medical Affairs, reporting to David A. Hollander, MD, MBA, Aerie’s Chief Research & Development Officer. Dr. Senchyna will lead and direct the clinical development and
- ProQR Receives Rare Pediatric Disease Designation from FDA for QR-421ahttps://modernod.com/news/proqr-receives-rare-pediatric-disease-designation-from-fda-for-qr-421a/2477267/ProQR Therapeutics announced that it received Rare Pediatric Disease (RPD) designation from the FDA for QR-421a for the treatment of patients with retinitis pigmentosa caused by mutations in exon 13 of the USH2A gene. QR-421a is a first-in-class investigational RNA-based oligonucl
- EyePoint Pharmaceuticals and Ocumension Therapeutics Sign License Agreement to Develop and Commercialize Dexycu in China, Hong Kong, Macau, and Taiwanhttps://modernod.com/news/eyepoint-pharmaceuticals-and-ocumension-therapeutics-sign-license-agreement-to-develop-and-commercialize-dexycu-in-china-hong-kong-macau-and-taiwan/2477260/EyePoint Pharmaceuticals and Ocumension Therapeutics announced an exclusive license agreement for the development and commercialization of Dexycu (dexamethasone intraocular suspension) 9% for the treatment of postoperative inflammation following ocular surgery in Mainland China, Hong Kong, Macau
- Alexander van der Mey Named New CCO at Optimo Medical AGhttps://modernod.com/news/alexander-van-der-mey-named-new-cco-at-optimo-medical-ag/2477248/As of January 16, Alexander van der Mey assumed the role of chief commercial officer (CCO) position of Optimo Medical AG. In his new position, Mr. van der Mey is responsible for global marketing and sales. Mr. Van der Mey has studied business administration in Germany and the Netherlands.
- AOA Receives Department of Justice Approval to Expand Group Purchasing Activities for Its AOAExcel Membershttps://modernod.com/news/aoa-receives-department-of-justice-approval-to-expand-group-purchasing-activities-for-its-aoaexcel-members/2477244/The Department of Justice (DOJ) announced January 15 that it will not challenge a proposal by the American Optometric Association to expand its group purchasing organization’s (GPO) activities to include the purchase of optometric products for resale to consumers, specifically eyeglass lenses, fr
- The Vision Council Notes That U.S.-China Trade Agreement Will Result in Tariff Reductions on Certain Optical Productshttps://modernod.com/news/the-vision-council-notes-that-u-s-china-trade-agreement-will-result-in-tariff-reductions-on-certain-optical-products/2477239/The trade deal between the US and China that requires structural reforms to China’s economic and trade regimes will also lead to a modification of a portion of the existing Section 301 China tariffs, according to The Vision Council, as
- Genentech/Roche Initiate First Diabetic Macular Edema Phase 3 Trial of the Port Delivery System with Ranibizumabhttps://modernod.com/news/genentech-roche-initiate-first-diabetic-macular-edema-phase-3-trial-of-the-port-delivery-system-with-ranibizumab/2477233/Genentech and Roche have initiated a new phase 3 clinical trial investigating the Port Delivery System with ranibizumab (PDS) in people with diabetic macular edema (DME). The PDS is an investigational first-of-its-kind refillable eye implant designed to continuously release a customized formulati
- Exonate Announces Collaboration With Janssen to Develop a New Eye Drop for the Treatment of Retinal Vascular Diseaseshttps://modernod.com/news/exonate-announces-collaboration-with-janssen-to-develop-a-new-eye-drop-for-the-treatment-of-retinal-vascular-diseases/2477223/Exonate, an early stage biotechnology company, announced that it has entered into a strategic collaboration agreement with Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson. Through the collaboration, Exonate will work with Janssen Research & Development scientists to develop an
- Watchdog: NHS Delays Responsible for Glaucoma Patients Going Blindhttps://modernod.com/news/watchdog-nhs-delays-responsible-for-glaucoma-patients-going-blind/2477221/Long delays to treatment on the NHS have been responsible for glaucoma patients losing their sight, a safety watchdog in the UK has warned, according to a report in Independent. The